News

XenoPort’s randomized, parallel-group, double-blind, placebo-controlled Phase II clinical trial of XP19986 is designed to evaluate the efficacy, safety and tolerability of a sustained-release formulation of XP19986 (designated as

Under the terms of the agreement, Centocor will have rights to utilize the deltaPhase technology in their research. PhaseBio’s deltaPhase technology is said to offer new solutions for

The Phase III trials will compare apricitabine (ATC) to the current standard of care in HIV–infected patients who are resistant to current drugs. The program is being conducted

James Hutchinson and his team will remain in senior management roles in the combined Sunrise/American Clinical Services (ACS) business. The ACS transaction follows on from the recently completed

In order to finalize the structural and operational details, both parties have agreed to extend the current letter of intent to January 31, 2008. Under the proposed agreement

The company said that shipment of these products has commenced. As the first company to file an abbreviated new drug application (ANDA) with a Paragraph IV patent certification

Pursuant to the definitive acquisition agreement, Arura has acquired all of the outstanding securities from the securities holders of Silkit for an aggregate base purchase price of CAD1

Shire expects the three additional dosage strengths of 20mg, 40mg and 60mg will be available in retail pharmacies in the second quarter of 2008 to supplement the existing

These studies will enroll in excess of 2,400 patients recruited globally. The GW642444 long-acting beta agonist (LABA) Phase IIb dose-optimization study will enroll approximately 600 patients with persistent